Ten Challenges in the Management of Neuroblastoma

• Spix C , PastoreG, SankilaRet al. Neuroblastoma incidence and survival in European children (1978–1997): report from the Automated Childhood Cancer Information System project. Eur. J. Cancer 42, 2081–2091 (2006).
   PubMed Web of Science ®Google Scholar
• Pearson AD , PinkertonCR, LewisIJ, ImesonJ, EllershawC, MachinD; European Neuroblastoma Study Group; Children’s Cancer and Leukaemia Group (CCLG formerly United Kingdom Children’s Cancer Study Group). High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.Lancet Oncol.9(3), 247–256 (2008).
   PubMed Web of Science ®Google Scholar
• Ladenstein R , Valteau-CouanetD, BrockPet al. Randomized trial of prophylactic granulocyte colony-stimulating factor during Rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J. Clin. Oncol. 28, 3516–3524 (2010).
   PubMed Web of Science ®Google Scholar
• Matthay KK , ReynoldsCP, SeegerRCet al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children’s Oncology Group study. J. Clin. Oncol. 27, 1007–1013 (2009).
   PubMed Web of Science ®Google Scholar
• Simon T , BertholdF, BorkhardtA, KremensB, De CarolisB, HeroB. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials.Pediatr. Blood Cancer56, 578–583 (2011).
   PubMed Web of Science ®Google Scholar
• Lehara T , HosoiH, AkazawaKet al. MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening. Br. J. Cancer 94, 1510–1515 (2006).
   PubMed Web of Science ®Google Scholar
• Cohn SL , PearsonADJ, LondonWBet al. The International Neuroblastoma Risk Group (INRG) Classification System: an INRG Task Force Report. J. Clin. Oncol. 27, 289–297 (2009).
   PubMed Web of Science ®Google Scholar
• Moroz V , MachinD, FaldumAet al. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur. J. Cancer 47, 561–571 (2011).
   PubMed Web of Science ®Google Scholar
• London WB , CastleberryRP, MatthayKKet al. Evidence for an age cut off greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J. Clin. Oncol. 23, 6459–6465 (2005).
   PubMed Web of Science ®Google Scholar
• De Bernadi B , GerrardM, BoniLet al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J. Clin. Oncol. 27, 1034–1040 (2009).
   PubMed Web of Science ®Google Scholar
• Evans AE , D’AngioGJ, RandolphJ. A proposed staging for children with neuroblastoma. Children’s cancer study group A.Cancer27(2), 374–378 (1971).
   PubMed Web of Science ®Google Scholar
• Brodeur GM , PritchardJ, BertholdFet al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol. 11(8), 1466–1477 (1993).
   PubMed Web of Science ®Google Scholar
• Monclair T , BrodeurGM, AmbrosPFet al. The International Neuroblastoma Risk Group (INRG) Staging System: an INRG Task Force Report. J. Clin. Oncol. 27, 298–303 (2009).
   PubMed Web of Science ®Google Scholar
• Simon T , HeroB, Benz-BohmGet al. Review of image defined risk factors on localized neuroblastoma patients: results of the GPOH NB96 trial. Pediatr. Blood Cancer 50, 965–969 (2008).
   PubMed Web of Science ®Google Scholar
• De Bernardi B , MosseriV, RubieHet al. Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br. J. Cancer 99, 1027–1033 (2008).
   PubMed Web of Science ®Google Scholar
• Bagatell R , Beck-PopovicM, LondonWBet al. Significance of MYCN amplification in International Neuroblastoma Staging System stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J. Clin. Oncol. 27, 365–370 (2009).
   PubMed Web of Science ®Google Scholar
• Canete A , GerrardM, RubieHet al. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Pediatric Oncology European Neuroblastoma Experience. J. Clin. Oncol. 27, 1014–1019 (2009).
   PubMed Web of Science ®Google Scholar
• Attiyeh EF , LondonWB, MosséYPet al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N. Engl. J. Med. 353, 2243–2253 (2005).
   PubMed Web of Science ®Google Scholar
• Vermeulen J , De PreterK, NaranjoAet al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol. 10, 663–671 (2009).
   PubMed Web of Science ®Google Scholar
• Ambros IS , BrunnerB, AignerGet al. A multilocus technique for risk evaluation of patients with neuroblastoma. Clin. Cancer Res. 17, 792–804 (2011).
   PubMed Web of Science ®Google Scholar
• Schleiermacher G , MichonJ, RibeiroAet al. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br. J. Cancer 105, 1940–1948 (2011).
   PubMed Web of Science ®Google Scholar
• Kushner BH , LaQuagliaMP, BonillaMAet al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J. Clin. Oncol. 12, 2607–2613 (1994).
   PubMed Web of Science ®Google Scholar
• Cheung NK , KushnerBH, LaQuagliaMet al. N7: a novel multi-modality therapy of high-risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med. Pediatr. Oncol. 36, 227–230 (2001).
   PubMedGoogle Scholar
• Schmidt M , SimonT, HeroBet al. The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur. J. Cancer 44, 1552–1558 (2008).
   PubMed Web of Science ®Google Scholar
• Valteau-Couanet D , MichonJ, BoneuAet al. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J. Clin. Oncol. 23, 532–540 (2005).
   PubMed Web of Science ®Google Scholar
• Kohler JA , EllershawC, MachinD; Neuroblastoma Working Group of the Children’s Cancer and Leukaemia Group. Response to N7 induction chemotherapy in children more than one year of age diagnosed with metastatic neuroblastoma treated in UKCCSG centers.Pediatr. Blood Cancer49, 234–239 (2007).
   PubMed Web of Science ®Google Scholar
• Park JR , ScottJR, StewartCFet al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children’s Oncology Group study. J. Clin. Oncol. 29, 4351–4357 (2011).
   PubMed Web of Science ®Google Scholar
• De Ioris M , CastellanoA, IlariIet al. Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma. Eur. J. Cancer 47, 572–578 (2011).
   PubMed Web of Science ®Google Scholar
• Veal GJ , ColeM, ErringtonJet al. Pharmacokinetics and metabolism of 13-cis-retinoic acid (isoretinoin) in children with high-risk neuroblastoma – a study of the United Kingdom Children’s Cancer Study Group. Br. J. Cancer 96, 424–431 (2007).
   PubMed Web of Science ®Google Scholar
• Villablanca JG , KrailoMD, AmesMMet al. Phase I trial of oral fenretinide in children with high risk solid tumours: a report from the Children’s Oncology Group (CCG 09709). J. Clin. Oncol. 24, 3423–3430 (2006).
   PubMed Web of Science ®Google Scholar
• Garaventa A , LukschR, Lo PiccoloMSet al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin. Cancer Res. 9, 2032–2039 (2003).
   PubMed Web of Science ®Google Scholar
• Maurer BJ , KalousO, YesairDWet al. Improved oral delivery of N-(4-hydroxyphenyl) retinamide with a novel LYM-X-SORB organized lipid complex. Clin. Cancer Res. 13, 3079–3086 (2007).
   PubMed Web of Science ®Google Scholar
• Gilman AL , OzkaynakMF, MatthayKKet al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem cell rescue: a report from the Children’s Oncology Group. J. Clin. Oncol. 27, 85–91 (2009).
   PubMed Web of Science ®Google Scholar
• Ozkaynak MF , SondelPM, KrailoMDet al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children’s Cancer Group Study. J. Clin. Oncol. 18, 4077–4085 (2000).
   PubMed Web of Science ®Google Scholar
• Yu AL , GilmanAL, OzkaynakMFet al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isoretinoin for neuroblastoma. N. Engl. J. Med. 363, 1324–1334 (2010).
   PubMed Web of Science ®Google Scholar
• Castel V , SeguraV, CañeteA. Treatment of high-risk neuroblastoma with anti-GD2 antibodies.Clin. Transl Oncol.12, 788–793 (2010).
   PubMed Web of Science ®Google Scholar
• Brisse HJ , McCarvilleMB, GranataCet al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology 261, 243–257 (2011).
   PubMed Web of Science ®Google Scholar
• Matthay KK , ShulkinB, LadenstainRet al. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br. J. Cancer 102, 1319–1326 (2010).
   PubMed Web of Science ®Google Scholar
• Melzer HI , CoppenrathE, SchmidIet al. 123I-mIBG scintigraphy/SPECT versus 18F FDG PET in paediatric neuroblastoma. Eur. J. Nucl. Med. Mol. Imaging38, 1648–1658 (2011).
   PubMed Web of Science ®Google Scholar
• Sharp SE , ShulkinBL, GelfandMJet al. 123I-mIBG scintigraphy and 18F-FDG PET in neuroblastoma. J. Nucl. Med.50, 1237–1243 (2009).
   PubMed Web of Science ®Google Scholar
• Papathanasiou ND , GazeMN, SullivanPet al. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis. J. Nucl. Med.52, 519–525 (2011).
   PubMed Web of Science ®Google Scholar
• Taggart DR , HanMM, QuachAet al. Comparison of iodine-123 metaiodobenzylguanidine (mIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 mIBG therapy for relapsed neuroblastoma. J. Clin. Oncol. 27, 5343–5349 (2009).
   PubMed Web of Science ®Google Scholar
• Kroiss A , PutzerD, UprimnyCet al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur. J. Nucl. Med. Mol. Imaging 38, 865–873 (2011).
   PubMed Web of Science ®Google Scholar
• Fiebrich HB , BrouwersAH, KerstensMNet al. 6-[F-18]fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J. Clin. Endocrinol. Metab. 94, 3922–3930 (2009).
   PubMed Web of Science ®Google Scholar
• Timmers HJ , ChenCC, CarrasquilloJAet al. Comparison of 18F-fluoro-L-DOPA, 18F fluoro-deoxyglucose, and 18F-flurodopamine PET and 123I-mIBG scintigraphy in the localization of phaeochromocytoma and paraganglioma. J. Clin. Endocrinol. Metab. 94, 4757–4767 (2009).
   PubMed Web of Science ®Google Scholar
• Piccardo A , LopciE, ConteMet al. Comparison of 18F-dopa PET/CT and 123I-mIBG scinitigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur. J. Nucl. Med. Mol. Imaging 39, 57–71 (2012).
   PubMed Web of Science ®Google Scholar
• Beiske K , BurchillSA, CheungIYet al. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br. J. Cancer 100, 1627–1637 (2009).
   PubMed Web of Science ®Google Scholar
• Garaventa A , ParodiS, De BernardiBet al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur. J. Cancer 45, 2835–2842 (2009).
   PubMed Web of Science ®Google Scholar
• London WB , CastelV, MonclairTet al. Clinical and biological features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group Project. J. Clin. Oncol. 29, 3286–3292 (2011).
   PubMed Web of Science ®Google Scholar
• Rubie H , ChisholmJ, DefachellesASet al. Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Société Français des Cancers de l’Enfant and United Kingdom Children Cancer Study Group – New Agents Group Study. J. Clin. Oncol. 24, 5259–5264 (2006).
   PubMed Web of Science ®Google Scholar
• Vassal G , GiammarileF, BrooksMet al. A Phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Français d’Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG). Eur. J. Cancer 44, 2453–2460 (2008).
   PubMed Web of Science ®Google Scholar
• Garaventa A , LukschR, BiasottiSet al. A Phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer 98, 2488–2494 (2003).
   PubMed Web of Science ®Google Scholar
• Simon T , LänglerA, BertholdFet al. Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a Phase 2 trial. J. Pediatr. Hematol. Oncol. 29, 101–106 (2007).
   PubMed Web of Science ®Google Scholar
• Simon T , LänglerA, HarnischmacherUet al. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a Phase-II trial. J. Cancer Res. Clin. Oncol. 133, 653–661 (2007).
   PubMed Web of Science ®Google Scholar
• Wagner LM , VillablancaJG, StewartCFet al. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a New Approach to Neuroblastoma Therapy Consortium Study. J. Clin. Oncol. 27, 1290–1296 (2009).
   PubMed Web of Science ®Google Scholar
• Rubie H , GeorgerB, FrappazDet al. Phase I study of topotecan in combination with temozolamide (TOTEM) in relapsed or refractory paediatric solid tumours. Eur. J. Cancer 46, 2763–2770 (2010).
   PubMed Web of Science ®Google Scholar
• London WB , FrantzCN, CampbellLAet al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children’s Oncology Group Study. J. Clin. Oncol. 28, 3808–3815 (2010).
   PubMed Web of Science ®Google Scholar
• Bagatell R , LondonWB, WagnerLBet al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children’s Oncology Group Study. J. Clin. Oncol. 29, 208–213 (2011).
   PubMed Web of Science ®Google Scholar
• Kushner BH , KramerK, ModakSet al. High-dose carboplatin–irinotecan–temozolomide: treatment option for neuroblastoma resistant to topotecan. Pediatr. Blood Cancer 56, 403–408 (2011).
   PubMed Web of Science ®Google Scholar
• Kushner BH , KramerK, ModakSet al. High-dose cyclophosphamide–irinotecan–vincristine for primary refractory neuroblastoma. Eur. J. Cancer 47, 84–89 (2011).
   PubMed Web of Science ®Google Scholar
• Kushner B , KramerK, ModakS, QinL, CheungN. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma.Cancer116, 3054–3060 (2010).
   PubMed Web of Science ®Google Scholar
• Minturn JE , EvansAE, VillablancaJGet al. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a New Approaches to Neuroblastoma Therapy Consortium Study. Cancer Chemother. Pharmacol. 68, 1057–1065 (2011).
   PubMed Web of Science ®Google Scholar
• Fouladi M , ParkJR, StewartCFet al. Pediatric Phase I trial and pharmacokinetic study of vorinostat: a Children’s Oncology Group Phase I Consortium Report. J. Clin. Oncol. 28, 3623–3629 (2010).
   PubMed Web of Science ®Google Scholar
• Fox E , AplencR, BagatellRet al. A Phase I trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor inhibitor, in children and adolescents with refractory solid tumors. J. Clin. Oncol. 35, 5174–5181 (2010).
   Google Scholar
• Fox E , MarisJM, CohnSLet al. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemother. Pharmacol. 66, 737–743 (2010).
   PubMed Web of Science ®Google Scholar
• Spunt SL , GruppSA, VikTA. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.J. Clin. Oncol.29, 2933–2940 (2011).
   PubMed Web of Science ®Google Scholar
• Geoerger B , KieranMW, GruppSet al. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur. J. Cancer 48, 253–262 (2012).
   PubMed Web of Science ®Google Scholar
• Øra I , EggertA. Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research.Semin. Cancer Biol.21, 217–228 (2011).
   PubMed Web of Science ®Google Scholar
• Russell HZ , GroshenSG, AraTet al. A Phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a New Approaches to Neuroblastoma Therapy (NANT) Study. Pediatr. Blood Cancer 57, 275–282 (2011).
   PubMed Web of Science ®Google Scholar
• Matthay KK , YanikG, MessinaJet al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J. Clin. Oncol. 25, 1054–1060 (2007).
   PubMed Web of Science ®Google Scholar
• Matthay KK , TanJC, VillablancaJGet al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a New Approaches to Neuroblastoma Therapy Consortium Study. J. Clin. Oncol. 24, 500–506 (2006).
   PubMed Web of Science ®Google Scholar
• Matthay KK , QuachA, HubertyJet al. Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a New Approaches to Neuroblastoma Therapy Phase I study. J. Clin. Oncol. 27, 1020–1025 (2009).
   PubMed Web of Science ®Google Scholar
• Gaze M , ChangY, FluxGet al. Feasibility of dosimetry based high dose 131mIBG with topotecan as a radiosensitiser in children with metastatic neuroblastoma. Cancer Biother. Radiopharm. 20(2), 195–199 (2005).
   PubMed Web of Science ®Google Scholar
• More SS , ItsaraM, YangXet al. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model. Clin. Cancer Res. 17, 2339–2349 (2011).
   PubMed Web of Science ®Google Scholar
• Menda Y , O’DorisioMS, MadsenMet al. Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumours that express somatostatin receptors. J. Nucl. Med. 51, 1524–1531 (2010)
   PubMed Web of Science ®Google Scholar
• Gains JE , BomanjiJB, FershtNLet al. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J. Nucl. Med.52, 1041–1047 (2011).
   PubMed Web of Science ®Google Scholar
• Kramer K , KushnerB, HellerG, CheungNK. Neuroblastoma metastatic to the central nervous system.Cancer91, 1510–1519 (2001).
   PubMed Web of Science ®Google Scholar
• Kushner BH , KramerK, ModakSet al. Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system. Bone Marrow Transplant. 37, 271–276 (2006).
   PubMed Web of Science ®Google Scholar
• Kramer K , KushnerBH, ModakSet al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J. Neurooncol. 97, 409–418 (2010).
   PubMed Web of Science ®Google Scholar
• Croog VJ , KramerK, CheungNKet al. Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastoma. Int. J. Radiat. Oncol. Biol. Phys. 78, 849–854 (2010).
   PubMed Web of Science ®Google Scholar
• Rubie H , De BernadiB, GerrardMet al. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J. Clin. Oncol. 29, 449–455 (2010).
   PubMed Web of Science ®Google Scholar
• Kushner B , BudnickA, KramerKet al. Ototoxicity form high-dose use of platinum compounds in patients with neuroblastoma. Cancer 107, 417–422 (2006).
   PubMed Web of Science ®Google Scholar
• Neuwelt EA , BrockP. Critical need for international consensus on ototoxicity assessment criteria.J. Clin. Oncol.28, 1630–1632 (2010).
   PubMed Web of Science ®Google Scholar
• Li Y , WomerRB, SiberJH. Predicting cisplatin ototoxicity in children: the influence of age and cumulative dose.Eur. J. Cancer40, 2445–2451 (2004).
   PubMed Web of Science ®Google Scholar
• Fisher MJ , LangeBJ, NeedleMNet al. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy. Pediatr. Blood Cancer 43, 780–784 (2004).
   PubMed Web of Science ®Google Scholar
• Katzenstein HM , ChangK, KrailoMet al. A randomized study of platinum based chemotherapy with or without amifostine for the treatment of children with hepatoblastoma (HB): a report of the Intergroup Hepatoblastoma Study P9645. Am. Soc. Clin. Oncol. 22(14 Suppl.), Abstract 8518 (2004).
   PubMedGoogle Scholar
• Marina N , ChangKW, MalogolowkinMet al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors. A Children’s Oncology Group Study. Cancer 104, 841–847 (2005).
   PubMed Web of Science ®Google Scholar
• Fouladi M , ChintagumpalaM, AshleyDet al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medullobalstoma. J. Clin. Oncol. 26, 3749–3755 (2008).
   PubMed Web of Science ®Google Scholar
• Simon T , HeroB, BongartzRet al. Intensified external beam radiation therapy improves the outcome of stage 4 neuroblastoma in children >1 with residual local disease. Strahlenther. Onkol. 182, 389–394 (2006).
   PubMed Web of Science ®Google Scholar
• Gatcombe HG , MarcusRBJr, KatzensteinHMet al. Excellent local control from radiation therapy for high-risk neuroblastoma. Int. J. Radiat. Oncol. Biol. Phys. 74(5), 1549–1554 (2009).
   PubMed Web of Science ®Google Scholar
• Pai Panandiker AS , McGregorL, KrasinMJet al. Locoregional tumor progression after radiation therapy influences overall survival in pediatric patients with neuroblastoma. Int. J. Radiat. Oncol. Biol. Phys. 76(4), 1161–1165 (2010).
   PubMed Web of Science ®Google Scholar
• Paulino AC , FerenciMS, ChiangKYet al. Comparison of conventional to intensity modulated radiation therapy for abdominal neuroblastoma. Pediatr. Blood Cancer 46, 739–744 (2006).
   PubMed Web of Science ®Google Scholar
• Shaffer R , VollansE, VellaniRet al. A radiotherapy planning study of RapidArc, intensity modulated radiotherapy, three-dimensional conformal radiotherapy, and parallel opposed beams in the treatment of pediatric retroperitoneal tumors. Pediatr. Blood Cancer 56, 16–23 (2011).
   PubMed Web of Science ®Google Scholar
• Hall EJ . Intensity-modulated radiation therapy, protons, and the risk of second cancers.Int. J. Radiat. Oncol. Biol. Phys.65, 1–7 (2006).
   PubMed Web of Science ®Google Scholar
• Schneider U , LomaxA, TimmermannB. Second cancers in children treated with modern radiotherapy techniques.Radiother. Oncol.89, 135–140 (2008).
   PubMed Web of Science ®Google Scholar
• Hattangadi JA , RombiB, YockTIet al. Proton radiotherapy for high-risk pediatric neuroblastoma: early outcomes and dose comparison. Int. J. Radiat. Oncol. Biol. Phys. 83(3), 1015–1022 (2012).
   PubMed Web of Science ®Google Scholar
• Laverdière C , LiuQ, YasuiYet al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J. Natl Cancer Inst. 101, 1131–1140 (2009).
   PubMed Web of Science ®Google Scholar
• Perwein T , LacknerH, SovinzPet al. Survival and late effects in children with stage 4 neuroblastoma. Pediatr. Blood Cancer 57, 629–635 (2001).
   Google Scholar
• Grunfeld E . Looking beyond survival: how are we looking at survivorship?J. Clin. Oncol.24, 5166–5169 (2006).
   PubMed Web of Science ®Google Scholar
• Meadows AT . Pediatric cancer survivorship: research and clinical care.J. Clin. Oncol.24, 5160–5165 (2006).
   PubMed Web of Science ®Google Scholar
• Conte M , ParodiS, De BernardiBet al. Neuroblastoma in adolescents: the Italian experience. Cancer 106(6), 1409–1417 (2006).
   PubMed Web of Science ®Google Scholar
• Castel V , VillamónE, CañeteAet al. Neuroblastoma in adolescents: genetic and clinical characterisation. Clin. Transl Oncol. 12(1), 49–54 (2010).
   PubMed Web of Science ®Google Scholar
• Esiashvili N , GoodmanM, WardK, MarcusRBJr, JohnstonePA. Neuroblastoma in adults: incidence and survival analysis based on SEER data.Pediatr. Blood Cancer49, 41–46 (2007).
   PubMed Web of Science ®Google Scholar
• Podda MG , LukschR, PolastriDet al. Neuroblastoma in patients over 12 years old: a 20-year experience at the Istituto Nazionale Tumori of Milan. Tumori 96(5), 684–689 (2010).
   PubMed Web of Science ®Google Scholar
• Polishchuk AL , DuboisSG, Haas-KoganD, HawkinsR, MatthayKK. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults.Cancer117, 4286–4293 (2011).
   PubMed Web of Science ®Google Scholar
• Hansard HC . Vol. 502, Col. 308WH–314WH (16 December 2009).
   Google Scholar
• Hansard HC . Vol. 507, Col. 226WH–232WH (16 March 2010).
   Google Scholar

Websites

• National Registry of Childhood Tumours Progress Report (2010). www.ncin.org.uk/view.aspx?rid=492
   Google Scholar
• National Cancer Institute at the NIH. Phase III Randomized Study of Sodium Thiosulfate in Preventing Ototoxicity in Young Patients Receiving Cisplatin Chemotherapy for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy. www.cancer.gov/clinicaltrials/search/view?cdrid=588655&version=HealthProfessional
   Google Scholar
• National Cancer Survivorship Initiative. Children and Young People. www.ncsi.org.uk/what-we-are-doing/children-young-people
   Google Scholar